ClinicalTrials.gg
Not yet recruitingNCT07060911Updated Nov 12, 2026

Pivotal Study to Assess Safety and Performance of Neola®, a Novel Lung Monitoring Device for Neonates

An interventional study of Lung monitoring with the Neola device in RDS of Prematurity, Preterm Birth and Lung Diseases, sponsored by Neola Medical Inc. Not yet recruiting at 2 sites in United States. Open to participants aged 1 Day to 44 Weeks. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Neola Medical Inc · Not applicable, Interventional, and Other

How we know

Updated Nov 12, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
1 Day to 44 Weeks
Sex
All
01

Study summary

Pivotal study to assess safety and performance of Neola®, a novel lung monitoring device for neonates

Read the detailed description

The purpose of the study is to demonstrate that the device is safe and performs as intended under anticipated use conditions.

The performance of Neola will be evaluated in terms of ability to continuously measure and display the relative lung volume and absolute oxygen gas concentration during standard NICU procedures on neonates.

02

Conditions studied

  • RDS of Prematurity
  • Preterm Birth
  • Lung Diseases

Keywords

  • GASMAS
  • Spectroscopy
  • Gas absorption spectroscopy
03

In context

Respiratory Distress Syndrome In Premature Infants

34 studies on the registry are indexed under Respiratory Distress Syndrome In Premature Infants; 10 are open to participants now.

This study's planned enrollment of 22 is below the median of 45 across 29 interventional studies indexed under Respiratory Distress Syndrome In Premature Infants.

Browse Respiratory Distress Syndrome In Premature Infants studies →

Lead sponsor

This is the only study on the registry with Neola Medical Inc as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 44 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

IInclusion criteria:

  • Preterm or term born neonates with gestational age between 26 and 40 weeks
  • Age between 1 day post-natal and 44 weeks corrected gestational age
  • Weight between 1000 g and 3500 g
  • Patient treated at a neonatal intensive care unit.
  • Patient is either on invasive mechanical ventilation, on CPAP or NIPPV or receives respiratory support via high-flow nasal cannula (≥2L/min)
  • Signed prior to any study related procedures by the legal representatives of the patient

Exclusion criteria:

  • Known cardiopulmonary congenital anomalies
  • Patients with trisomies or other chromosomal abnormality
  • Patients not expected to survive
  • Non-intact skin or other skin conditions (such as skin lesions) that do not allow the use of skin adhesives. (e.g., Bullous impetigo, Staphylococcal scalded skin syndrome, localized lesions of herpes simplex virus)
  • Thorax curvature does not allow placement of the probe sets without air between the surface of the probes and the skin.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Lung monitoring with the Neola device

    Device: Lung monitoring with the Neola device

Interventions

  • DeviceLung monitoring with the Neola device

    Lung monitoring with the Neola device

06

What researchers measure

Primary outcomes

  1. The number of device related events including skin reactions

    The primary objective of the study is to evaluate safety with regards to adverse events (AE) and in particular device related adverse events. Outcome measure: The number of device related events including skin reactions.

    Time frame: 2 days

  2. The number of serious and non-serious adverse events occurring during the trial

    The primary objective of the study is to evaluate safety with regards to adverse events (AE) and in particular device related adverse events. Outcome measure: The number of serious and non-serious adverse events occurring during the trial.

    Time frame: 2 days

Secondary outcomes

  1. The device's ability to continuously measure and present the clinical parameters while the neonates are in a resting state/sleeping

    This endpoint will be presented as the percentage of the total resting/sleeping time that the device is able to measure the clinical parameters relative lung volume and absolute oxygen concentration.

    Time frame: 7 days

  2. The device's ability to continuously measure and present the clinical parameters during normal handling of the neonates

    This endpoint will be presented as the percentage of the total handling time that the device is able to measure the clinical parameters relative lung volume and absolute oxygen concentration.

    Time frame: 7 days

  3. The adhesive performance of the probes in terms of ability to be repositioned and stay attached

    The adhesive performance of the probes in terms of ability to be repositioned and stay attached. This exploratory endpoint will be evaluated the percentage of probe adhesives that were able to stay attached for the duration of the measurement session

    Time frame: 7 days

Other outcomes

  1. Evaluate the correlation between Neola® measured clinical data and clinical data available from other monitoring devices, procedures or tests.

    The endpoint will be valuated using diagnostic methods such as, but not limited to: peripheral oxygen saturation (SpO2), x-ray images, Blood gas analysis data (partial pressure of oxygen (PaO2) and carbon dioxide (PaCO2)), respiratory support settings, respiratory rate, heart rate, blood pressure.

    Time frame: 7 days

07

Study locations

2 sites
  • Stanford Lucile Packard Children's Hospital Neonatal Intensive Care Unit
    Palo Alto, California 94304, United States
    • Valerie Chock, M.D., M.S. Epi · Contactvchock@stanford.edu · (650) 497-8800
    • Valerie Chock, M.D., M.S. Epi · Principal investigator
  • Cooper Health System
    Camden, New Jersey 08103, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jun 2027; primary completion for Jun 2028, 12 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Mar 2026 → Jun 2027, primary completion Dec 2026 → Jun 2028 and completion Feb 2027 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 11, 2025
StartEst.
Jun 2027was Mar 2026
Primary completionEst.
Jun 2028was Dec 2026
CompletionEst.
Dec 2029was Feb 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 2026→Jun 2027
Nov 12, 2026
Primary completion
Dec 2026→Jun 2028
Nov 12, 2026
Study completion
Feb 2027→Dec 2029
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Mar 2026→Jun 2027
    Primary completion Dec 2026→Jun 2028
    Study completion Feb 2027→Dec 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07060911
Lead sponsor
Neola Medical Inc
Responsible party
Sponsor
First posted
Jul 11, 2025
Start date
Jun 2027 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Magnus Johnsson, MSc.
Contact
magnus.johnsson@neolamedical.com
+46336163410
Valerie Chock, M.D., M.S. Epi
principal investigator · Division of Neonatal and Developmental Medicine Stanford University School of Medicine
Vineet Bhandari, MD, DM
principal investigator · Department of Pediatrics The Children's Regional Hospital at Cooper

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion